Surgical site infections (“SSIs”) are among the costliest of healthcare-associated infections and are the second most common in the US.1, 2, 3 SSIs can lead to prolonged patient suffering, extended hospitalizations, and, in some cases, patient death. SSIs cost the healthcare industry billions of dollars each year, much of which is no longer reimbursable through medical insurance providers in
MediClear PreOp, the only dual antimicrobial pre-surgical film barrier, was designed to help hospitals reduce infections by protecting surgical sites on patients before a surgical procedure. MediClear PreOp reduces the level of pathogens on the patient’s skin while protecting the surgical site from exposure to bacteria found within the hospital environment.
“It has become clear that there is a gap in the protection of patients from exposure to bacteria before a surgical procedure, and that gap can be filled by MediClear PreOp,” said
Covalon surveyed dozens of clinical Key Opinion Leaders at last month’s
Covalon will further validate the need for MediClear PreOp at the Association of periOperative Nurses Global Surgical Conference & Expo (“AORN”) from
Since Covalon’s launch of this innovative product, the medical technology industry has recognized MediClear PreOp as an innovative presurgical protocol with a number of awards. MediClear PreOp was the recipient of the 2018 New Product Innovation Award for Surgical Site Infection Prevention by
MediClear PreOp is based on Covalon’s proprietary antimicrobial silicone adhesive technology and harnesses the synergistic effects of silver and chlorhexidine, killing 99.99% of microorganisms associated with SSIs on patients’ skin within 30 minutes of application and suppressing regrowth until surgery. Clinical evidence of well-known antimicrobial agents, such as chlorhexidine, in washes and wipes has shown that they are effective at reducing the levels of bacteria on a patient’s skin pre-operatively and subsequently decreasing the incidence of SSIs when utilized correctly.
Most SSIs are caused by the native flora of the patient’s skin, mucous membranes, or hollow viscera.4 When the skin is incised, the underlying tissue is exposed to endogenous flora, increasing the risk of potential infection. It has been shown that preoperative skin preparation products containing chlorhexidine, like MediClear PreOp, help to decrease endogenous and exogenous pathogens, reduce the risk of SSIs and subsequent mortality.5 Furthermore, MediClear PreOp’s soft silicone adhesive is gentle on the skin, while the breathable polyurethane backing provides a physical barrier to external contamination, such as bacteria, yeast, and viruses.
To learn more about
|Brian Pedlar, CEO, Covalon Technologies Ltd.|
|Phone:||905.568.8400 x 233|
1. Watanabe A. Kohnoe S. Shimabukuro R, et al., Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery. Surg Today. 2008, 38, 404-412.
3. Scott, D, The Direct Medical Costs of Healthcare-Associated Infections in US Hospitals and the Benefits of Prevention,
4. Altemeir WA, Culbertson WR, Hummel RP, Surgical consideration of endogenous infections-sources, types and methods of control.
5. Eiselt D, Presurgical skin preparation with a novel 2% chlorhexidine gluconate cloth reduces rates of surgical site infection in orthopaedic surgical patients. Orthop Nurs 2009, 28, 141-145.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.